# Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

> **NCT06235918** · PHASE2 · UNKNOWN · sponsor: **Xiang Lu** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinomas
- Resectable Head and Neck Squamous-cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06235918
- **Lead sponsor:** Xiang Lu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235918, "Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06235918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*